| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 181 | 2023 | 1173 | 31.200 |
Why?
|
| Bronchoscopy | 53 | 2022 | 147 | 13.440 |
Why?
|
| Early Detection of Cancer | 57 | 2023 | 454 | 11.270 |
Why?
|
| Solitary Pulmonary Nodule | 27 | 2020 | 77 | 9.980 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 47 | 2021 | 300 | 8.890 |
Why?
|
| Tomography, X-Ray Computed | 67 | 2022 | 2324 | 5.880 |
Why?
|
| Mass Screening | 37 | 2023 | 843 | 5.560 |
Why?
|
| Multiple Pulmonary Nodules | 11 | 2020 | 41 | 5.550 |
Why?
|
| Neoplasm Staging | 49 | 2021 | 800 | 4.020 |
Why?
|
| Smoking | 34 | 2022 | 1452 | 3.490 |
Why?
|
| Endosonography | 22 | 2020 | 177 | 3.300 |
Why?
|
| Humans | 256 | 2023 | 68618 | 2.860 |
Why?
|
| Patient Participation | 7 | 2022 | 146 | 2.730 |
Why?
|
| Lung | 21 | 2022 | 849 | 2.540 |
Why?
|
| Pulmonary Medicine | 13 | 2019 | 31 | 2.300 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 508 | 2.240 |
Why?
|
| Pulmonologists | 3 | 2021 | 5 | 2.020 |
Why?
|
| Lung Diseases | 6 | 2014 | 175 | 1.980 |
Why?
|
| Biopsy, Needle | 20 | 2020 | 191 | 1.960 |
Why?
|
| Male | 123 | 2023 | 37321 | 1.960 |
Why?
|
| Aged | 84 | 2021 | 14862 | 1.920 |
Why?
|
| Decision Making | 10 | 2022 | 410 | 1.920 |
Why?
|
| Female | 121 | 2023 | 38074 | 1.890 |
Why?
|
| Pneumonectomy | 11 | 2019 | 79 | 1.760 |
Why?
|
| Smoking Cessation | 12 | 2022 | 1034 | 1.730 |
Why?
|
| Clinical Competence | 16 | 2017 | 657 | 1.700 |
Why?
|
| United States | 41 | 2022 | 7367 | 1.690 |
Why?
|
| Middle Aged | 89 | 2021 | 21147 | 1.660 |
Why?
|
| Image-Guided Biopsy | 6 | 2020 | 17 | 1.590 |
Why?
|
| Positron-Emission Tomography | 9 | 2020 | 160 | 1.570 |
Why?
|
| Diagnostic Imaging | 4 | 2020 | 201 | 1.510 |
Why?
|
| Fluoroscopy | 4 | 2020 | 152 | 1.470 |
Why?
|
| Robotic Surgical Procedures | 2 | 2020 | 49 | 1.350 |
Why?
|
| Lymph Nodes | 10 | 2014 | 258 | 1.300 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2021 | 504 | 1.300 |
Why?
|
| Exercise | 6 | 2021 | 658 | 1.300 |
Why?
|
| Biopsy, Fine-Needle | 7 | 2019 | 76 | 1.270 |
Why?
|
| Prospective Studies | 30 | 2022 | 3705 | 1.240 |
Why?
|
| Pandemics | 3 | 2020 | 352 | 1.230 |
Why?
|
| Radiography, Thoracic | 9 | 2020 | 99 | 1.210 |
Why?
|
| Tobacco Products | 4 | 2020 | 234 | 1.200 |
Why?
|
| Neoplasms | 7 | 2021 | 1667 | 1.190 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 4 | 2021 | 16 | 1.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 207 | 1.180 |
Why?
|
| Proteomics | 2 | 2020 | 246 | 1.160 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 143 | 1.150 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 154 | 1.140 |
Why?
|
| Palliative Care | 7 | 2016 | 271 | 1.140 |
Why?
|
| Risk Assessment | 19 | 2021 | 2007 | 1.110 |
Why?
|
| Propofol | 2 | 2022 | 36 | 1.100 |
Why?
|
| Conscious Sedation | 5 | 2022 | 61 | 1.070 |
Why?
|
| Ultrasonography, Interventional | 4 | 2018 | 119 | 1.030 |
Why?
|
| Adult | 67 | 2022 | 21403 | 1.010 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 4848 | 1.010 |
Why?
|
| Sensitivity and Specificity | 20 | 2019 | 1753 | 0.950 |
Why?
|
| Biopsy | 8 | 2022 | 540 | 0.940 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 109 | 0.930 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 261 | 0.930 |
Why?
|
| Hypnotics and Sedatives | 4 | 2022 | 96 | 0.910 |
Why?
|
| Communication | 2 | 2019 | 329 | 0.890 |
Why?
|
| Health Policy | 4 | 2015 | 221 | 0.880 |
Why?
|
| Carcinoma, Bronchogenic | 6 | 2006 | 18 | 0.880 |
Why?
|
| Electromagnetic Phenomena | 5 | 2019 | 25 | 0.870 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2011 | 373 | 0.830 |
Why?
|
| Education, Medical, Continuing | 2 | 2014 | 136 | 0.830 |
Why?
|
| Tobacco Industry | 2 | 2014 | 55 | 0.820 |
Why?
|
| Bronchoscopes | 4 | 2013 | 9 | 0.820 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2012 | 52 | 0.810 |
Why?
|
| Oncologists | 1 | 2021 | 9 | 0.800 |
Why?
|
| Surgeons | 2 | 2021 | 68 | 0.800 |
Why?
|
| Smokers | 2 | 2020 | 200 | 0.780 |
Why?
|
| Cohort Studies | 13 | 2022 | 2358 | 0.770 |
Why?
|
| Attitude to Health | 4 | 2013 | 403 | 0.770 |
Why?
|
| Tobacco Use Disorder | 4 | 2020 | 432 | 0.750 |
Why?
|
| Spirometry | 1 | 2020 | 47 | 0.740 |
Why?
|
| Disease Management | 4 | 2019 | 248 | 0.730 |
Why?
|
| Health Communication | 1 | 2020 | 19 | 0.730 |
Why?
|
| Medically Uninsured | 1 | 2021 | 99 | 0.720 |
Why?
|
| Lymphatic Metastasis | 14 | 2012 | 274 | 0.710 |
Why?
|
| Terminal Care | 5 | 2016 | 92 | 0.710 |
Why?
|
| Health Personnel | 2 | 2020 | 286 | 0.700 |
Why?
|
| Mediastinum | 8 | 2019 | 39 | 0.690 |
Why?
|
| Guideline Adherence | 5 | 2021 | 287 | 0.680 |
Why?
|
| Surveys and Questionnaires | 14 | 2021 | 2800 | 0.680 |
Why?
|
| Quality of Life | 12 | 2022 | 1515 | 0.670 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 767 | 0.670 |
Why?
|
| Predictive Value of Tests | 14 | 2020 | 1465 | 0.670 |
Why?
|
| Uveal Neoplasms | 1 | 2019 | 16 | 0.660 |
Why?
|
| Survival Rate | 13 | 2020 | 1056 | 0.660 |
Why?
|
| Incidental Findings | 2 | 2017 | 42 | 0.660 |
Why?
|
| Biomarkers | 3 | 2020 | 1593 | 0.640 |
Why?
|
| Probability | 7 | 2017 | 245 | 0.640 |
Why?
|
| Physicians | 3 | 2017 | 324 | 0.640 |
Why?
|
| Risk Factors | 19 | 2020 | 5731 | 0.630 |
Why?
|
| Patient Care | 1 | 2019 | 61 | 0.630 |
Why?
|
| Thoracic Surgery | 2 | 2015 | 72 | 0.620 |
Why?
|
| Prognosis | 15 | 2019 | 2093 | 0.610 |
Why?
|
| Mediastinal Neoplasms | 6 | 2016 | 27 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 10 | 2020 | 772 | 0.610 |
Why?
|
| Fellowships and Scholarships | 4 | 2017 | 127 | 0.610 |
Why?
|
| Carcinoma, Small Cell | 6 | 2010 | 53 | 0.600 |
Why?
|
| Bronchi | 6 | 2016 | 59 | 0.590 |
Why?
|
| Patient Compliance | 1 | 2020 | 402 | 0.590 |
Why?
|
| ErbB Receptors | 2 | 2011 | 239 | 0.590 |
Why?
|
| Education, Medical, Graduate | 3 | 2017 | 214 | 0.580 |
Why?
|
| Trees | 1 | 2017 | 8 | 0.580 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 106 | 0.580 |
Why?
|
| Ultrasonography | 4 | 2020 | 453 | 0.580 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 468 | 0.570 |
Why?
|
| Attitude of Health Personnel | 5 | 2021 | 442 | 0.570 |
Why?
|
| Critical Care | 3 | 2013 | 263 | 0.570 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 107 | 0.570 |
Why?
|
| Tomography, Spiral Computed | 3 | 2016 | 57 | 0.550 |
Why?
|
| Consensus | 5 | 2020 | 211 | 0.550 |
Why?
|
| Monitoring, Ambulatory | 2 | 2016 | 84 | 0.550 |
Why?
|
| Exercise Therapy | 1 | 2018 | 183 | 0.540 |
Why?
|
| Sputum | 3 | 2015 | 51 | 0.540 |
Why?
|
| Radiation Dosage | 7 | 2019 | 419 | 0.540 |
Why?
|
| Incidence | 11 | 2020 | 1603 | 0.530 |
Why?
|
| Cost-Benefit Analysis | 12 | 2022 | 504 | 0.520 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 307 | 0.520 |
Why?
|
| Patient Selection | 7 | 2021 | 592 | 0.510 |
Why?
|
| Precision Medicine | 2 | 2018 | 111 | 0.510 |
Why?
|
| Melanoma | 1 | 2019 | 335 | 0.500 |
Why?
|
| Radiosurgery | 3 | 2014 | 66 | 0.500 |
Why?
|
| Respiratory Mechanics | 1 | 2015 | 33 | 0.500 |
Why?
|
| Feasibility Studies | 7 | 2022 | 652 | 0.490 |
Why?
|
| Diagnosis, Differential | 9 | 2020 | 1140 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 468 | 0.490 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 81 | 0.480 |
Why?
|
| Antineoplastic Agents | 5 | 2006 | 1070 | 0.460 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 3259 | 0.460 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 498 | 0.450 |
Why?
|
| Sarcoidosis | 2 | 2016 | 77 | 0.450 |
Why?
|
| Culture | 1 | 2013 | 75 | 0.450 |
Why?
|
| Prevalence | 4 | 2020 | 1619 | 0.430 |
Why?
|
| Mediastinal Diseases | 2 | 2010 | 15 | 0.430 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2012 | 29 | 0.430 |
Why?
|
| Simian Immunodeficiency Virus | 2 | 2012 | 28 | 0.430 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 2077 | 0.430 |
Why?
|
| Retinal Drusen | 1 | 2012 | 2 | 0.430 |
Why?
|
| Gene Expression | 1 | 2015 | 770 | 0.420 |
Why?
|
| Caregivers | 2 | 2008 | 365 | 0.420 |
Why?
|
| Models, Biological | 2 | 2016 | 981 | 0.400 |
Why?
|
| Anesthesia, Local | 1 | 2011 | 14 | 0.400 |
Why?
|
| Motor Activity | 1 | 2015 | 621 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 104 | 0.390 |
Why?
|
| Health Status | 3 | 2018 | 429 | 0.390 |
Why?
|
| Analgesia | 1 | 2011 | 58 | 0.380 |
Why?
|
| Anesthetics, Local | 1 | 2011 | 83 | 0.380 |
Why?
|
| Quality of Health Care | 1 | 2013 | 322 | 0.370 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2012 | 145 | 0.370 |
Why?
|
| DNA, Mitochondrial | 6 | 1994 | 84 | 0.360 |
Why?
|
| Analgesics | 1 | 2011 | 118 | 0.360 |
Why?
|
| Endoscopy | 4 | 2012 | 464 | 0.360 |
Why?
|
| Area Under Curve | 4 | 2020 | 238 | 0.350 |
Why?
|
| Liability, Legal | 1 | 2010 | 19 | 0.350 |
Why?
|
| Veterans | 2 | 2016 | 904 | 0.350 |
Why?
|
| Retrospective Studies | 20 | 2021 | 7277 | 0.350 |
Why?
|
| Pneumothorax | 3 | 2022 | 42 | 0.340 |
Why?
|
| Lymphocele | 1 | 2009 | 3 | 0.340 |
Why?
|
| Cadaver | 3 | 2019 | 136 | 0.330 |
Why?
|
| Age Factors | 6 | 2020 | 1864 | 0.330 |
Why?
|
| Clinical Trials as Topic | 7 | 2011 | 848 | 0.330 |
Why?
|
| Terminally Ill | 1 | 2008 | 17 | 0.330 |
Why?
|
| ROC Curve | 5 | 2017 | 392 | 0.320 |
Why?
|
| Treatment Refusal | 1 | 2008 | 40 | 0.320 |
Why?
|
| Hospice Care | 1 | 2008 | 29 | 0.320 |
Why?
|
| Betacoronavirus | 2 | 2020 | 116 | 0.320 |
Why?
|
| Respiration, Artificial | 2 | 2004 | 190 | 0.320 |
Why?
|
| Databases, Factual | 2 | 2021 | 622 | 0.310 |
Why?
|
| Software | 1 | 2011 | 418 | 0.310 |
Why?
|
| Combined Modality Therapy | 6 | 2012 | 951 | 0.300 |
Why?
|
| Occupational Exposure | 2 | 2020 | 122 | 0.300 |
Why?
|
| Mortality | 2 | 2016 | 163 | 0.300 |
Why?
|
| Physicians, Primary Care | 3 | 2013 | 46 | 0.300 |
Why?
|
| Unnecessary Procedures | 2 | 2019 | 49 | 0.290 |
Why?
|
| Accelerometry | 2 | 2018 | 61 | 0.290 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 74 | 0.280 |
Why?
|
| Societies, Medical | 7 | 2018 | 403 | 0.280 |
Why?
|
| Health Services Accessibility | 2 | 2008 | 581 | 0.280 |
Why?
|
| Point Mutation | 4 | 1994 | 97 | 0.270 |
Why?
|
| Light | 1 | 2007 | 152 | 0.270 |
Why?
|
| Genetic Testing | 2 | 2019 | 159 | 0.270 |
Why?
|
| Multimodal Imaging | 2 | 2018 | 62 | 0.270 |
Why?
|
| South Carolina | 11 | 2018 | 2752 | 0.270 |
Why?
|
| Mediastinoscopy | 8 | 2019 | 13 | 0.260 |
Why?
|
| Pilot Projects | 5 | 2021 | 1342 | 0.260 |
Why?
|
| Tumor Burden | 2 | 2020 | 132 | 0.260 |
Why?
|
| Early Diagnosis | 3 | 2014 | 122 | 0.260 |
Why?
|
| Disease Progression | 4 | 2018 | 1038 | 0.260 |
Why?
|
| Survival Analysis | 6 | 2019 | 714 | 0.250 |
Why?
|
| Intubation, Intratracheal | 2 | 2004 | 99 | 0.250 |
Why?
|
| Radiologic Health | 2 | 2021 | 2 | 0.250 |
Why?
|
| Radiography | 3 | 2015 | 572 | 0.250 |
Why?
|
| Infection Control | 1 | 2005 | 101 | 0.240 |
Why?
|
| Cross Infection | 2 | 2006 | 195 | 0.240 |
Why?
|
| Developing Countries | 1 | 2005 | 106 | 0.240 |
Why?
|
| Educational Status | 2 | 2021 | 273 | 0.230 |
Why?
|
| Patients | 2 | 2010 | 69 | 0.230 |
Why?
|
| Mitochondrial Myopathies | 2 | 1994 | 2 | 0.230 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 323 | 0.230 |
Why?
|
| Dogs | 2 | 2015 | 490 | 0.220 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2008 | 17 | 0.220 |
Why?
|
| Decision Support Techniques | 3 | 2013 | 191 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 1998 | 529 | 0.220 |
Why?
|
| Adenocarcinoma | 6 | 2019 | 475 | 0.220 |
Why?
|
| Epilepsies, Myoclonic | 2 | 1993 | 8 | 0.220 |
Why?
|
| Religion and Medicine | 1 | 2003 | 25 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2012 | 129 | 0.220 |
Why?
|
| Frostbite | 1 | 2022 | 1 | 0.220 |
Why?
|
| Data Collection | 3 | 2013 | 420 | 0.220 |
Why?
|
| Motivation | 3 | 2018 | 561 | 0.210 |
Why?
|
| Visual Acuity | 5 | 2012 | 236 | 0.210 |
Why?
|
| Medical Overuse | 1 | 2023 | 28 | 0.210 |
Why?
|
| Tomography, Emission-Computed | 4 | 2003 | 40 | 0.210 |
Why?
|
| Counseling | 4 | 2020 | 280 | 0.210 |
Why?
|
| State Government | 2 | 2014 | 34 | 0.210 |
Why?
|
| Thoracic Surgery, Video-Assisted | 4 | 2011 | 19 | 0.210 |
Why?
|
| Chronic Disease | 3 | 2022 | 1330 | 0.210 |
Why?
|
| Treatment Outcome | 11 | 2014 | 7029 | 0.210 |
Why?
|
| Bupropion | 1 | 2022 | 63 | 0.210 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 166 | 0.200 |
Why?
|
| Bronchial Thermoplasty | 1 | 2021 | 1 | 0.200 |
Why?
|
| Vital Signs | 1 | 2022 | 19 | 0.200 |
Why?
|
| Young Adult | 8 | 2018 | 5717 | 0.200 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 76 | 0.200 |
Why?
|
| Global Health | 2 | 2015 | 136 | 0.200 |
Why?
|
| Community Health Planning | 1 | 2021 | 19 | 0.200 |
Why?
|
| Logistic Models | 6 | 2016 | 1420 | 0.200 |
Why?
|
| Algorithms | 2 | 2019 | 1196 | 0.190 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 378 | 0.190 |
Why?
|
| Confidence Intervals | 3 | 2011 | 242 | 0.190 |
Why?
|
| Equipment Design | 4 | 2013 | 500 | 0.190 |
Why?
|
| False Positive Reactions | 4 | 2016 | 95 | 0.190 |
Why?
|
| Eligibility Determination | 1 | 2021 | 31 | 0.190 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2014 | 106 | 0.190 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2020 | 16 | 0.190 |
Why?
|
| Pancreas Transplantation | 2 | 1998 | 71 | 0.190 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 37 | 0.180 |
Why?
|
| Firefighters | 1 | 2020 | 13 | 0.180 |
Why?
|
| Health Surveys | 2 | 2021 | 489 | 0.180 |
Why?
|
| Risk | 3 | 2017 | 563 | 0.180 |
Why?
|
| Insurance Coverage | 1 | 2021 | 99 | 0.180 |
Why?
|
| Resource Allocation | 1 | 2020 | 35 | 0.180 |
Why?
|
| Phenotype | 3 | 2020 | 947 | 0.180 |
Why?
|
| Cisplatin | 2 | 2010 | 192 | 0.170 |
Why?
|
| Costs and Cost Analysis | 3 | 2012 | 193 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 2279 | 0.170 |
Why?
|
| Exercise Test | 3 | 2016 | 242 | 0.170 |
Why?
|
| Life Expectancy | 2 | 2014 | 51 | 0.170 |
Why?
|
| Evidence-Based Medicine | 6 | 2018 | 438 | 0.170 |
Why?
|
| Brain Neoplasms | 3 | 2003 | 371 | 0.160 |
Why?
|
| Postoperative Period | 2 | 2014 | 238 | 0.160 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2003 | 26 | 0.160 |
Why?
|
| Medicare | 1 | 2021 | 319 | 0.160 |
Why?
|
| Mental Recall | 1 | 2019 | 72 | 0.160 |
Why?
|
| Cell Phone Use | 1 | 2018 | 4 | 0.160 |
Why?
|
| Reinforcement, Social | 1 | 2018 | 7 | 0.160 |
Why?
|
| Midazolam | 1 | 2018 | 46 | 0.160 |
Why?
|
| Preventive Health Services | 1 | 2019 | 86 | 0.160 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 307 | 0.160 |
Why?
|
| Diabetic Nephropathies | 2 | 1998 | 161 | 0.150 |
Why?
|
| Text Messaging | 1 | 2018 | 47 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 4 | 2019 | 369 | 0.150 |
Why?
|
| Comorbidity | 2 | 2021 | 1426 | 0.150 |
Why?
|
| Food Preferences | 1 | 2018 | 46 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 792 | 0.150 |
Why?
|
| Benzodiazepines | 1 | 2018 | 130 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 306 | 0.150 |
Why?
|
| Endophthalmitis | 3 | 2006 | 15 | 0.150 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 40 | 0.150 |
Why?
|
| Asthma | 1 | 2021 | 345 | 0.150 |
Why?
|
| Functional Residual Capacity | 1 | 2017 | 3 | 0.150 |
Why?
|
| Smoking Prevention | 3 | 2012 | 259 | 0.150 |
Why?
|
| Breath Holding | 1 | 2017 | 8 | 0.150 |
Why?
|
| Genomics | 2 | 2016 | 168 | 0.150 |
Why?
|
| Respiration | 2 | 2017 | 91 | 0.150 |
Why?
|
| Retinal Vessels | 1 | 2018 | 74 | 0.150 |
Why?
|
| Phantoms, Imaging | 2 | 2009 | 189 | 0.150 |
Why?
|
| Forests | 1 | 2017 | 9 | 0.150 |
Why?
|
| Thoracoscopy | 1 | 2017 | 6 | 0.140 |
Why?
|
| Remote Sensing Technology | 1 | 2016 | 4 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 756 | 0.140 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 284 | 0.140 |
Why?
|
| United Kingdom | 3 | 2012 | 152 | 0.140 |
Why?
|
| Education, Medical | 2 | 2015 | 147 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 38 | 0.140 |
Why?
|
| Linear Models | 2 | 2009 | 521 | 0.140 |
Why?
|
| Pulmonary Blastoma | 1 | 1996 | 7 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 1998 | 121 | 0.140 |
Why?
|
| Regression Analysis | 3 | 2015 | 737 | 0.140 |
Why?
|
| Accreditation | 1 | 2017 | 72 | 0.140 |
Why?
|
| Mitochondrial Encephalomyopathies | 2 | 1994 | 3 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 2 | 1998 | 365 | 0.140 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2016 | 20 | 0.130 |
Why?
|
| Pancoast Syndrome | 1 | 2015 | 2 | 0.130 |
Why?
|
| Patient Preference | 2 | 2013 | 57 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 1174 | 0.130 |
Why?
|
| User-Computer Interface | 1 | 2017 | 230 | 0.130 |
Why?
|
| Walking | 1 | 2018 | 241 | 0.130 |
Why?
|
| Radiopharmaceuticals | 2 | 2014 | 114 | 0.130 |
Why?
|
| Hemorrhage | 2 | 2022 | 328 | 0.130 |
Why?
|
| Eye Infections, Bacterial | 2 | 2006 | 15 | 0.130 |
Why?
|
| Adolescent | 11 | 2012 | 8912 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 333 | 0.130 |
Why?
|
| Lymphoma | 1 | 2016 | 116 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 425 | 0.130 |
Why?
|
| Lymphatic Diseases | 2 | 2016 | 27 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 536 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 629 | 0.120 |
Why?
|
| Computer Systems | 1 | 2014 | 42 | 0.120 |
Why?
|
| Cataract Extraction | 2 | 2006 | 127 | 0.120 |
Why?
|
| RNA, Transfer, Leu | 1 | 1994 | 5 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 74 | 0.120 |
Why?
|
| Learning Curve | 1 | 2014 | 20 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2017 | 310 | 0.120 |
Why?
|
| Movement | 1 | 2015 | 179 | 0.120 |
Why?
|
| Cause of Death | 1 | 2015 | 241 | 0.120 |
Why?
|
| Pain Management | 1 | 2015 | 186 | 0.110 |
Why?
|
| Hotlines | 1 | 2014 | 51 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2017 | 326 | 0.110 |
Why?
|
| Ophthalmoplegia, Chronic Progressive External | 1 | 1993 | 1 | 0.110 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 214 | 0.110 |
Why?
|
| Animals | 5 | 2015 | 20881 | 0.110 |
Why?
|
| Brain Diseases, Metabolic | 1 | 1993 | 9 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2016 | 431 | 0.110 |
Why?
|
| Time Factors | 4 | 2017 | 4655 | 0.110 |
Why?
|
| Alcoholism | 1 | 2022 | 1109 | 0.110 |
Why?
|
| Retinal Neovascularization | 1 | 1993 | 7 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 35 | 0.110 |
Why?
|
| Diagnostic Errors | 2 | 2011 | 100 | 0.110 |
Why?
|
| Puerto Rico | 1 | 2013 | 31 | 0.110 |
Why?
|
| RNA, Transfer, Lys | 1 | 1992 | 1 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1994 | 106 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2009 | 596 | 0.110 |
Why?
|
| Tracheostomy | 1 | 1993 | 31 | 0.110 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2013 | 100 | 0.110 |
Why?
|
| Macaca mulatta | 2 | 2012 | 77 | 0.110 |
Why?
|
| Dyspnea | 1 | 1993 | 87 | 0.110 |
Why?
|
| Curriculum | 1 | 2017 | 575 | 0.110 |
Why?
|
| Population Surveillance | 3 | 2012 | 285 | 0.110 |
Why?
|
| Asbestos | 2 | 2016 | 7 | 0.110 |
Why?
|
| Patient Simulation | 1 | 2013 | 64 | 0.100 |
Why?
|
| Enterocytes | 1 | 2012 | 7 | 0.100 |
Why?
|
| Immunity, Mucosal | 1 | 2012 | 19 | 0.100 |
Why?
|
| Photography | 1 | 2012 | 37 | 0.100 |
Why?
|
| Taxes | 1 | 2012 | 31 | 0.100 |
Why?
|
| Imidazoles | 1 | 2013 | 175 | 0.100 |
Why?
|
| Cellular Senescence | 1 | 2013 | 112 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2006 | 1553 | 0.100 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 281 | 0.100 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 1 | 2012 | 1 | 0.100 |
Why?
|
| History, 19th Century | 1 | 2012 | 95 | 0.100 |
Why?
|
| Product Labeling | 1 | 2012 | 43 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2013 | 172 | 0.100 |
Why?
|
| Forecasting | 2 | 2009 | 277 | 0.100 |
Why?
|
| Reimbursement Mechanisms | 1 | 2012 | 37 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2012 | 127 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 206 | 0.100 |
Why?
|
| Self Report | 1 | 2013 | 371 | 0.100 |
Why?
|
| Macular Degeneration | 1 | 2012 | 75 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2011 | 880 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 231 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2012 | 248 | 0.100 |
Why?
|
| Weight Loss | 2 | 2005 | 319 | 0.100 |
Why?
|
| Colon | 1 | 2012 | 168 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 127 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2012 | 116 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2014 | 448 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 170 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2008 | 955 | 0.090 |
Why?
|
| Reference Standards | 2 | 2008 | 115 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2012 | 201 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2018 | 1738 | 0.090 |
Why?
|
| Nursing Staff | 1 | 2010 | 30 | 0.090 |
Why?
|
| Pedigree | 4 | 1994 | 159 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 931 | 0.090 |
Why?
|
| Observer Variation | 1 | 2011 | 330 | 0.090 |
Why?
|
| Preoperative Care | 2 | 2011 | 275 | 0.090 |
Why?
|
| Retinal Detachment | 1 | 1989 | 14 | 0.090 |
Why?
|
| Manikins | 1 | 2009 | 42 | 0.090 |
Why?
|
| Health Educators | 1 | 2009 | 3 | 0.080 |
Why?
|
| Italy | 2 | 2006 | 36 | 0.080 |
Why?
|
| Program Evaluation | 2 | 2009 | 502 | 0.080 |
Why?
|
| SAIDS Vaccines | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cercocebus | 1 | 2009 | 2 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 177 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2003 | 100 | 0.080 |
Why?
|
| Cancer Care Facilities | 1 | 2008 | 32 | 0.080 |
Why?
|
| Retinitis Pigmentosa | 1 | 2008 | 17 | 0.080 |
Why?
|
| Attitude to Death | 1 | 2008 | 52 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1745 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 70 | 0.080 |
Why?
|
| Thorax | 2 | 2018 | 49 | 0.080 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2008 | 15 | 0.080 |
Why?
|
| Lenses, Intraocular | 1 | 1989 | 96 | 0.080 |
Why?
|
| Base Sequence | 4 | 1994 | 1015 | 0.080 |
Why?
|
| Serial Learning | 1 | 2008 | 4 | 0.080 |
Why?
|
| Mutation | 2 | 1992 | 1213 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2008 | 15 | 0.080 |
Why?
|
| Oxygen Consumption | 2 | 2003 | 258 | 0.080 |
Why?
|
| Home Care Services | 1 | 2008 | 84 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 215 | 0.080 |
Why?
|
| Radiotherapy | 2 | 2005 | 86 | 0.080 |
Why?
|
| Immunity, Innate | 1 | 2009 | 156 | 0.080 |
Why?
|
| Muscles | 5 | 1994 | 158 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2010 | 328 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2550 | 0.070 |
Why?
|
| Respiratory System | 1 | 2007 | 28 | 0.070 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2007 | 2 | 0.070 |
Why?
|
| Research | 2 | 2018 | 214 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 226 | 0.070 |
Why?
|
| Bias | 1 | 2008 | 148 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 209 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 765 | 0.070 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 33 | 0.070 |
Why?
|
| Nutritional Sciences | 2 | 2005 | 21 | 0.070 |
Why?
|
| Obesity | 2 | 2005 | 1076 | 0.070 |
Why?
|
| Retina | 1 | 2008 | 252 | 0.070 |
Why?
|
| Bronchial Neoplasms | 1 | 2006 | 12 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 1447 | 0.070 |
Why?
|
| Students, Medical | 1 | 2009 | 210 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 786 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2007 | 143 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2006 | 48 | 0.070 |
Why?
|
| England | 1 | 2006 | 64 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2006 | 24 | 0.070 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2005 | 12 | 0.070 |
Why?
|
| Respiratory Function Tests | 3 | 2011 | 123 | 0.070 |
Why?
|
| Device Removal | 1 | 2007 | 100 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 58 | 0.070 |
Why?
|
| Protective Devices | 1 | 2005 | 13 | 0.070 |
Why?
|
| Community Networks | 1 | 2006 | 96 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2004 | 1615 | 0.060 |
Why?
|
| Quinazolines | 1 | 2005 | 70 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 84 | 0.060 |
Why?
|
| Physical Endurance | 1 | 2005 | 38 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 168 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 710 | 0.060 |
Why?
|
| Child | 8 | 2012 | 6405 | 0.060 |
Why?
|
| Body Composition | 1 | 2005 | 119 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 567 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 378 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2005 | 117 | 0.060 |
Why?
|
| Breathing Exercises | 2 | 1994 | 8 | 0.060 |
Why?
|
| Citrate (si)-Synthase | 2 | 1994 | 11 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1994 | 44 | 0.060 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2003 | 3 | 0.060 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2003 | 2 | 0.060 |
Why?
|
| MELAS Syndrome | 2 | 1993 | 3 | 0.060 |
Why?
|
| Nucleic Acid Conformation | 2 | 1994 | 92 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 1994 | 159 | 0.050 |
Why?
|
| Muscular Diseases | 2 | 1994 | 41 | 0.050 |
Why?
|
| Diet, Reducing | 1 | 2003 | 46 | 0.050 |
Why?
|
| Interview, Psychological | 1 | 2003 | 113 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 39 | 0.050 |
Why?
|
| Telomerase | 1 | 2003 | 85 | 0.050 |
Why?
|
| Stents | 1 | 2007 | 657 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2002 | 26 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 58 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2002 | 43 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 301 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 186 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 73 | 0.050 |
Why?
|
| Heart Failure | 1 | 2010 | 1180 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 43 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 733 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2002 | 328 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 150 | 0.050 |
Why?
|
| Hospices | 1 | 2000 | 14 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2000 | 24 | 0.050 |
Why?
|
| Forced Expiratory Volume | 2 | 2016 | 87 | 0.050 |
Why?
|
| Community Health Services | 1 | 2021 | 141 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2010 | 125 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2018 | 867 | 0.050 |
Why?
|
| Markov Chains | 1 | 2001 | 133 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 186 | 0.040 |
Why?
|
| Tobacco | 1 | 2021 | 161 | 0.040 |
Why?
|
| Baltimore | 1 | 2019 | 34 | 0.040 |
Why?
|
| Proteins | 1 | 2003 | 474 | 0.040 |
Why?
|
| Catheter Ablation | 2 | 2012 | 229 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 319 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2019 | 47 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2010 | 239 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2019 | 4 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2003 | 334 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1046 | 0.040 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 1998 | 4 | 0.040 |
Why?
|
| Nuns | 1 | 2018 | 1 | 0.040 |
Why?
|
| Ireland | 1 | 2018 | 13 | 0.040 |
Why?
|
| Red Meat | 1 | 2018 | 10 | 0.040 |
Why?
|
| Venules | 1 | 2018 | 8 | 0.040 |
Why?
|
| Dairy Products | 1 | 2018 | 13 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 334 | 0.040 |
Why?
|
| Arterioles | 1 | 2018 | 40 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 940 | 0.040 |
Why?
|
| General Surgery | 1 | 1998 | 95 | 0.040 |
Why?
|
| Fruit | 1 | 2018 | 86 | 0.040 |
Why?
|
| Vegetables | 1 | 2018 | 76 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 1998 | 88 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 1998 | 174 | 0.040 |
Why?
|
| Grounded Theory | 1 | 2016 | 20 | 0.040 |
Why?
|
| SEER Program | 1 | 2017 | 153 | 0.030 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 104 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 703 | 0.030 |
Why?
|
| Vital Capacity | 1 | 2016 | 43 | 0.030 |
Why?
|
| Survivors | 1 | 1998 | 256 | 0.030 |
Why?
|
| Living Donors | 1 | 1998 | 160 | 0.030 |
Why?
|
| Deep Sedation | 1 | 2016 | 11 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2017 | 110 | 0.030 |
Why?
|
| Needles | 1 | 2016 | 34 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 52 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 38 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 247 | 0.030 |
Why?
|
| Agriculture | 1 | 2016 | 54 | 0.030 |
Why?
|
| Polysomnography | 1 | 1996 | 92 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1995 | 22 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 374 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 498 | 0.030 |
Why?
|
| Simulation Training | 1 | 2016 | 49 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1995 | 166 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 413 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 369 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2014 | 7 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2015 | 115 | 0.030 |
Why?
|
| Hypertension | 2 | 2018 | 1535 | 0.030 |
Why?
|
| Bone and Bones | 1 | 1995 | 145 | 0.030 |
Why?
|
| Ophthalmoplegia | 1 | 1994 | 20 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1994 | 37 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 2223 | 0.030 |
Why?
|
| Sleep | 1 | 1996 | 263 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 729 | 0.030 |
Why?
|
| Sports | 1 | 1994 | 55 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2013 | 40 | 0.030 |
Why?
|
| MERRF Syndrome | 1 | 1993 | 1 | 0.030 |
Why?
|
| Acute Disease | 2 | 2006 | 658 | 0.030 |
Why?
|
| Leigh Disease | 1 | 1993 | 3 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 24 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 1994 | 117 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1994 | 107 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 51 | 0.030 |
Why?
|
| Telephone | 1 | 2014 | 160 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2013 | 37 | 0.030 |
Why?
|
| Contraindications | 1 | 1993 | 52 | 0.030 |
Why?
|
| Psychotropic Drugs | 1 | 1993 | 83 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1993 | 94 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2013 | 49 | 0.030 |
Why?
|
| Thoracic Neoplasms | 1 | 1992 | 10 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 95 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 97 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 1993 | 57 | 0.030 |
Why?
|
| Physical Examination | 1 | 1993 | 152 | 0.030 |
Why?
|
| S Phase | 1 | 1992 | 38 | 0.030 |
Why?
|
| Vision, Binocular | 1 | 1993 | 30 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1993 | 141 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 95 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1992 | 60 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 8 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2012 | 9 | 0.030 |
Why?
|
| Acidosis, Lactic | 1 | 1992 | 6 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2012 | 147 | 0.030 |
Why?
|
| Interleukins | 1 | 2012 | 79 | 0.030 |
Why?
|
| Bromocriptine | 1 | 1991 | 8 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2012 | 62 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 2012 | 35 | 0.020 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1991 | 12 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 2012 | 43 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2014 | 346 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 146 | 0.020 |
Why?
|
| Oxygen | 1 | 1993 | 386 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1992 | 78 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 230 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 93 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1992 | 182 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1993 | 276 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 706 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2007 | 489 | 0.020 |
Why?
|
| Nicotine | 1 | 2014 | 350 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 64 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 59 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 53 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1998 | 839 | 0.020 |
Why?
|
| Infant | 2 | 1994 | 2891 | 0.020 |
Why?
|
| Health Behavior | 1 | 2014 | 458 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 689 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 349 | 0.020 |
Why?
|
| Northern Ireland | 1 | 1989 | 1 | 0.020 |
Why?
|
| Nurses | 1 | 2010 | 53 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2012 | 211 | 0.020 |
Why?
|
| Macular Edema | 1 | 1989 | 21 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 84 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 120 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 1174 | 0.020 |
Why?
|
| Social Class | 1 | 2009 | 127 | 0.020 |
Why?
|
| Electroretinography | 1 | 2008 | 122 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 274 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2008 | 88 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 267 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 320 | 0.020 |
Why?
|
| Family | 1 | 2010 | 293 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2008 | 62 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2008 | 29 | 0.020 |
Why?
|
| Space Perception | 1 | 2008 | 44 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1034 | 0.020 |
Why?
|
| Learning | 1 | 2009 | 186 | 0.020 |
Why?
|
| Myocardium | 1 | 1994 | 1204 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 63 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2008 | 79 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 332 | 0.020 |
Why?
|
| Mitochondria | 1 | 1992 | 643 | 0.020 |
Why?
|
| Tracheal Stenosis | 1 | 2007 | 21 | 0.020 |
Why?
|
| Vasculitis | 1 | 2007 | 33 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 137 | 0.020 |
Why?
|
| Trachea | 1 | 2007 | 48 | 0.020 |
Why?
|
| Uremia | 1 | 1966 | 10 | 0.020 |
Why?
|
| Masks | 1 | 2006 | 10 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 213 | 0.020 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2006 | 39 | 0.020 |
Why?
|
| Nitrogen | 1 | 1966 | 57 | 0.020 |
Why?
|
| Memory | 1 | 2008 | 214 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2006 | 44 | 0.020 |
Why?
|
| Sex Factors | 2 | 2005 | 1266 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1293 | 0.020 |
Why?
|
| Biliary Tract Diseases | 1 | 1966 | 50 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1641 | 0.020 |
Why?
|
| Necrosis | 1 | 2007 | 239 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 329 | 0.020 |
Why?
|
| Testosterone | 1 | 1966 | 96 | 0.020 |
Why?
|
| Pulmonary Emphysema | 1 | 2007 | 71 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 62 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 84 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 517 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2005 | 6 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2005 | 35 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2005 | 36 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2005 | 79 | 0.020 |
Why?
|
| Vitrectomy | 1 | 2004 | 21 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2004 | 27 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 2004 | 36 | 0.010 |
Why?
|
| Cognition | 1 | 2008 | 513 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 2689 | 0.010 |
Why?
|
| Cholesterol | 1 | 2005 | 331 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1966 | 307 | 0.010 |
Why?
|
| Carcinoma, Large Cell | 1 | 2003 | 6 | 0.010 |
Why?
|
| Pneumonia | 1 | 2004 | 110 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 76 | 0.010 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2003 | 37 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 2 | 1994 | 492 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2003 | 202 | 0.010 |
Why?
|
| Self Concept | 1 | 2003 | 132 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 2004 | 157 | 0.010 |
Why?
|
| Pulmonary Atelectasis | 1 | 2002 | 12 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2003 | 238 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2005 | 631 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1054 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2001 | 46 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2002 | 74 | 0.010 |
Why?
|
| Hospitalization | 1 | 2006 | 978 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 700 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1664 | 0.010 |
Why?
|
| Length of Stay | 1 | 2002 | 780 | 0.010 |
Why?
|
| Wakefulness | 1 | 1996 | 75 | 0.010 |
Why?
|
| Sleep, REM | 1 | 1996 | 93 | 0.010 |
Why?
|
| Ergometry | 1 | 1994 | 4 | 0.010 |
Why?
|
| Inhalation | 1 | 1994 | 11 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1994 | 18 | 0.010 |
Why?
|
| Respiratory Muscles | 1 | 1994 | 9 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 1536 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1994 | 78 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1996 | 418 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1996 | 1040 | 0.010 |
Why?
|
| Acid-Base Imbalance | 1 | 1993 | 3 | 0.010 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 1993 | 9 | 0.010 |
Why?
|
| Locomotion | 1 | 1994 | 135 | 0.010 |
Why?
|
| Cytochrome-c Oxidase Deficiency | 1 | 1993 | 1 | 0.010 |
Why?
|
| Mitochondria, Muscle | 1 | 1993 | 12 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1994 | 235 | 0.010 |
Why?
|
| Succinate Dehydrogenase | 1 | 1993 | 13 | 0.010 |
Why?
|
| Electron Transport Complex IV | 1 | 1993 | 33 | 0.010 |
Why?
|
| Ploidies | 1 | 1992 | 6 | 0.010 |
Why?
|
| Heart Rate | 1 | 1994 | 568 | 0.010 |
Why?
|
| Syndrome | 1 | 1992 | 255 | 0.010 |
Why?
|
| Medical Records | 1 | 1992 | 121 | 0.010 |
Why?
|
| Mothers | 1 | 1992 | 172 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1993 | 601 | 0.010 |
Why?
|
| DNA | 1 | 1993 | 597 | 0.010 |
Why?
|
| Aging | 1 | 1996 | 911 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1993 | 3187 | 0.000 |
Why?
|